US 12,475,984 B2
Techniques for providing interactive clinical decision support for drug dosage reduction
Robert Valuck, Denver, CO (US); and Thomas C. Ennis, Denver, CO (US)
Assigned to RXASSURANCE CORPORATION, Denver, CO (US)
Filed by RxAssurance Corporation, Denver, CO (US)
Filed on Aug. 5, 2020, as Appl. No. 16/985,972.
Claims priority of provisional application 62/882,788, filed on Aug. 5, 2019.
Prior Publication US 2021/0043293 A1, Feb. 11, 2021
Int. Cl. G16H 20/10 (2018.01); A61B 5/00 (2006.01); A61B 5/16 (2006.01); A61K 31/485 (2006.01); A61K 31/5513 (2006.01); G06N 3/045 (2023.01); G06N 3/08 (2023.01); G16H 10/60 (2018.01); G16H 40/67 (2018.01); G16H 50/20 (2018.01); G16H 50/70 (2018.01); G16H 70/20 (2018.01); G16H 70/40 (2018.01)
CPC G16H 20/10 (2018.01) [A61B 5/165 (2013.01); A61B 5/4848 (2013.01); A61B 5/7267 (2013.01); A61B 5/7275 (2013.01); A61K 31/485 (2013.01); A61K 31/5513 (2013.01); G06N 3/045 (2023.01); G06N 3/08 (2013.01); G16H 10/60 (2018.01); G16H 40/67 (2018.01); G16H 50/20 (2018.01); G16H 50/70 (2018.01); G16H 70/20 (2018.01); G16H 70/40 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A method of treating withdrawal symptoms associated with reduced dosage of a drug, comprising:
providing a patient, with access to a prescription support application configured to:
generate, an initial non-linear glide path of recommended dosages starting at an initial dosage of the drug associated with the withdrawal symptoms of the patient and ending at a goal dosage at an estimated time of arrival based on a guideline for the drug;
receive, from a patient interface, periodic patient monitoring including at least one drug withdrawal scale score, at least one anxiety scale score, and at least one indicated side effect;
determine, using one or more machine learning algorithms, a revised glide path starting at a current dosage of the drug associated with the withdrawal symptoms and ending at the goal dosage at a new estimated time of arrival based on a data record for the patient, the at least one drug withdrawal scale score and the at least one anxiety scale score for the patient, wherein determining the revised glide path comprises:
estimating a success probability of the initial non-linear glide path for the patient by applying a machine-learning model trained on labeled past outcomes of glide paths for other patients with withdrawal symptoms for the drug to the data record for the patient, the at least one drug withdrawal scale score, and the at least one anxiety scale score for the patient; and
determining that the estimated success probability of the initial non-linear glide path is less than a threshold probability;
recommending at least one medication or therapy for the indicated side effect;
determining a prescription adjustment of the drug for the patient based on the revised glide path; and
administering doses of the drug to the patient according to the adjusted prescription based on the revised glide path until reaching the goal dosage,
wherein the withdrawal symptoms are associated with a diagnosed Opioid Use Disorder, wherein the Opioid Use Disorder is specified for an opioid pain medication previously prescribed to the patient, wherein the drug is the opioid pain medication previously prescribed to the patient, and wherein the drug comprises a synthetic opioid other than methadone.